Fundz

Watching Monopar Therapeutics Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KMEDIUM RiskPositive

Monopar Therapeutics Inc.

Monopar Therapeutics
Filed: Jul 22, 2026CIK: 0001645469Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Monopar Therapeutics initiated a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease treatment, representing a significant milestone in advancing a rare disease therapeutic to market.

Key Takeaways

Rolling NDA submission for ALXN1840 began on July 22, 2026, accelerating the FDA review process

ALXN1840 targets Wilson disease, a rare genetic disorder with significant unmet medical needs

2 more takeaways

Related Filings (3)

3 more filings from Monopar Therapeutics Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJul 22, 2026
Item7.01
CategoryReg FD Disclosure
CIK0001645469
Accession #mnpr20260721_8k.htm
Risk LevelMEDIUM
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings

Monopar Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.